Hepatitis B Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and are able to understand and sign a consent form.
• People aged between 18 and 65 years old (inclusive).
• People who have tested positive for the hepatitis B surface antigen (HBsAg) for at least 6 months, or have other evidence confirming chronic hepatitis B.
• People who have previously been treated with interferon therapy, stopped that treatment at least 6 months before joining the trial, and whose HBsAg levels dropped by at least 80% by the end of their interferon treatment compared to when they started it.
• People whose HBsAg level is 500 IU/mL or below at the screening stage, and whose HBsAg has not risen by more than 50% compared to their level at the start of their previous interferon treatment.
• Women who could become pregnant must have a negative pregnancy test within 24 hours before the first dose, and all participants (male and female) must use effective contraception throughout the study.

Who may not be able to join:

• Women who are pregnant, breastfeeding, or planning to have a baby during the study period.
• People who have a personal or family history of mental health conditions, including depression, anxiety, mania, or schizophrenia.
• People whose chronic liver disease is caused by hepatitis A, hepatitis C, hepatitis E, HIV, alcohol, medications, autoimmune conditions, or other causes not related to hepatitis B.
• People with signs of sudden severe liver damage, indicated by significantly elevated liver enzyme (ALT) levels or high ALT combined with high bilirubin levels.
• People with signs of advanced liver disease that the liver can no longer compensate for, such as fluid build-up in the abdomen, internal bleeding from swollen veins in the food pipe or stomach, blood poisoning, confusion caused by liver failure, or kidney failure linked to liver disease — or any past history of such complications.
• People with evidence of liver cancer, or elevated levels of a liver cancer marker called AFP (confirm with trial site).
• People with kidney conditions such as nephritis, kidney insufficiency, or nephrotic syndrome, or whose blood creatinine level (a kidney function marker) is above the normal upper limit at screening.
• People whose blood test results show low levels of white blood cells (neutrophils), low platelet count, or low blood phosphorus levels (confirm with trial site for specific thresholds).
• People with certain other health conditions, including autoimmune diseases (such as psoriasis or lupus), thyroid disease, diabetes, high blood pressure that is not well controlled by medication, serious heart disease (particularly in the past 6 months), severe eye disease, or significant problems with other vital organs.
• People who are planning to have an organ transplant or who have already had one.
• People who are known to be allergic to the trial drug or any of its ingredients, or for whom the trial drug is otherwise medically unsuitable.
• People whom the trial investigators consider unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.